Bevacizumab
- PDF / 169,565 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 13 Downloads / 185 Views
1 S
Reversible posterior leukoencephalopathy syndrome: case report A retrospective study involving 31 patients with histologically proven metastatic colorectal cancer, who were prospectively registered across two centers in France and received treatment with bevacizumab between May 2005 and October 2006, described a patient [age and sex not stated], who developed reversible posterior leukoencephalopathy syndrome during treatment with bevacizumab for metastatic colorectal cancer. The patient had metastatic colorectal cancer, which had progressed under unspecified chemotherapy. Therefore, the patient started receiving bevacizumab 5 mg/kg infusion on day 1 every 2 weeks, followed by folinic acid [leucovorin] plus unspecified chemotherapeutic agent (irinotecan or oxaliplatin), followed by fluorouracil [5-fluorouracil]. The first bevacizumab infusion was given over 90 minutes, the second over 60 minutes and the following over 30 minutes. Thereafter, the patient developed generalised tonic-clonic seizure. Based on brain MRI, the patient was diagnosed with bevacizumab-induced reversible posterior leukoencephalopathy syndrome because of associated hypertension [duration of treatment to reaction onset not stated]. Therefore, the patient’s bevacizumab therapy was interrupted [outcome not stated]. Lievre A, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: A retrospective study. BMC Cancer 9: 347, 803499260 No. 347, 28 Sep 2009. Available from: URL: http://doi.org/10.1186/1471-2407-9-347
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
